Anti-CD279 (PD-1) Antibody Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 35+ Companies and Therapies | DelveInsight

New York, USA, July 26, 2023 (GLOBE NEWSWIRE) — Anti-CD279 (PD-1) Antibody Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 35+ Companies and Therapies | DelveInsight

The prevalence of cancer has been rising over the past few years, which prompts the growing demand for treatment options. The increasing prevalence of cancer and the growing research and development activities in developing Anti-CD279 (PD-1) Antibody therapies in treating various Cancers drives the market. The companies developing the potential therapies in the last stage of development include Junshi Biosciences,  Innovent Biologics, CStone Pharmaceuticals, and several others.

DelveInsight’s ‘Anti-CD279 (PD-1) Antibody Pipeline Insight 2023‘ report provides comprehensive global coverage of pipeline Anti-CD279 (PD-1) antibody therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Anti-CD279 (PD-1) antibody pipeline domain.

Key Takeaways from the Anti-CD279 (PD-1) Antibody Pipeline Report

• DelveInsight’s Anti-CD279 (PD-1) antibody pipeline report depicts a robust space with 35+ active players working to develop 40+ pipeline therapies for cancer treatment. 
• Key Anti-CD279 (PD-1) antibody companies such as GlaxoSmithKline, Innovent Biologics, BeiGene, Shanghai Junshi Biosciences, Agenus, Apollomics, CStone Pharmaceuticals, Bristol-Myers Squibb, Akeso Biopharma, Bright Peak Therapeutics, Jiangsu Hengrui Medicine, Arcus Biosciences, Pfizer, Hoffmann-La Roche, Qilu Pharmaceutical, Shanghai Henlius Biotech, Incyte Corporation, Revolka, GENUV, Prestige Biopharma, and others are evaluating new Anti-CD279 (PD-1) antibody drugs to improve the treatment landscape.
• Promising Anti-CD279 (PD-1) antibody in the pipeline such as Dostarlimab, Sintilimab, Tislelizumab, JS-003, Toripalimab, AGEN-2034, APL-501, CS-1003, Nivolumab, AK 105, AK-112, Lipustobart, Camrelizumab, Zimberelimab, Sasanlimab, RO 7247669, QL 1706, HLX-10, Retifanlimab, QL1604, RK-001, GNUV-205, PBP-2102, and others are under different phases of Anti-CD279 (PD-1) antibody clinical trials.
• In July 2023, Shanghai Junshi Biosciences Co., Ltd announced that the supplemental new drug application for toripalimab, the company’s anti-PD-1 monoclonal antibody, in combination with axitinib for the first-line treatment of patients with unresectable or metastatic renal cell carcinoma (“RCC”), has been accepted by the National Medical Products Administration (“NMPA”).
• In June 2023, Ocean Biomedical, Inc. announced that a new, broad U.S. patent for bispecific antibodies targeting chitinase 3-like-1 (CHi3L1) and programmed cell death protein 1 (PD-1), a promising new approach that has emerged from prior breakthrough discoveries that CHi3L1 is a “master regulator” of tumor growth in multiple visceral cancers, has been issued to one of its Scientific Co-founders, Dr. Jack A. Elias, MD.
• In May 2023, EQRx, Inc. provided written notice to CStone Pharmaceuticals of its termination of the Exclusive License Agreement dated October 26, 2020, between EQRx and CStone (as amended, the CStone Agreement), which termination will be effective in accordance with the terms of such agreement. The parties are in discussions regarding their respective transition obligations. Under the CStone Agreement, EQRx acquired a worldwide exclusive license for the research, development and commercialization of sugemalimab (EQ165) and nofazinlimab (EQ176), with the exception of mainland China, Taiwan, Hong Kong, and Macau.
• In April 2023, Specialised Therapeutics Asia Pte Ltd will partner with CTTQ-Akeso (Shanghai) Biomed. Tech. Co., Ltd.（jointly established by Akeso, Inc. and Chia Tai Tianqing Pharmaceutical Group Co., Ltd. to commercialize a new immuno-oncology therapy in Australia, Singapore and across Southeast Asia. The therapy ANNIKO (penpulimab) is an anti-PD1 monoclonal antibody currently under regulatory review by the US FDA for nasopharyngeal carcinoma – a difficult-to-treat form of head and neck cancer. Under the terms of the arrangement, ST will be responsible for all marketing, regulatory, and distribution activities in its key regions of Australia, Singapore, and across Southeast Asia. CTTQ-Akeso retains the rights of conducting any development work in relation to ANNIKO and Akeso retains all rights to product manufacture and supply.

Request a sample and discover the recent advances in Anti-CD279 (PD-1) antibody treatment drugs @ Anti-CD279 (PD-1) Antibody Pipeline Report

The Anti-CD279 (PD-1) antibody pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Anti-CD279 (PD-1) antibody drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Anti-CD279 (PD-1) antibody clinical trial landscape. 

Anti-CD279 (PD-1) Antibody Overview

PD-1 is a protein produced on T cells that belongs to the CD28 superfamily and conveys inhibitory signals when it interacts with its ligands PD-L1 and PD-L2. The PD-1 system appears to play critical roles in the regulation of autoimmunity, transplantation immunity, infectious immunity, and tumor immunity, according to mounting data. Because the interaction of PD-1 with its ligands occurs during the effector phase of killer T cell responses in peripheral blood, anti-PD-1 and anti-PD-L1 monoclonal antibodies are ideal as specific agents to augment T cell responses to tumors with fewer adverse events than CTLA-4 inhibition, which occurs during the priming phase of T cell responses within lymph nodes. The tolerability of PD-1-pathway blockers and their distinct mechanism of action has made them attractive backbones for the development of combination regimens. Combination treatments incorporating cytotoxic chemotherapy, anti-angiogenic medicines, alternative immune-checkpoint inhibitors, immunostimulatory cytokines, and cancer vaccines are now being studied in clinical trials.

Find out more about Anti-CD279 (PD-1) antibody @ Anti-CD279 (PD-1) Antibody Analysis

A snapshot of the Anti-CD279 (PD-1) Antibody Pipeline Drugs mentioned in the report:

Learn more about the emerging Anti-CD279 (PD-1) antibody @ Anti-CD279 (PD-1) Antibody Clinical Trials

Anti-CD279 (PD-1) Antibody Therapeutics Assessment

The Anti-CD279 (PD-1) antibody pipeline report proffers an integral view of the Anti-CD279 (PD-1) antibody emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

Scope of the Anti-CD279 (PD-1) Antibody Pipeline Report 

• Coverage: Global 
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Therapeutics Assessment By Route of Administration: Oral, Parenteral, Intravenous, Subcutaneous, Topical
• Therapeutics Assessment By Molecule Type: Monoclonal Antibody, Peptides, Polymer, Small molecule, Gene therapy
• Key Anti-CD279 (PD-1) Antibody Companies: GlaxoSmithKline, Innovent Biologics, BeiGene, Shanghai Junshi Biosciences, Agenus, Apollomics, CStone Pharmaceuticals, Bristol-Myers Squibb, Akeso Biopharma, Bright Peak Therapeutics, Jiangsu Hengrui Medicine, Arcus Biosciences, Pfizer, Hoffmann-La Roche, Qilu Pharmaceutical, Shanghai Henlius Biotech, Incyte Corporation, Revolka, GENUV, Prestige Biopharma and others
• Key Anti-CD279 (PD-1) Antibody in Pipeline: Dostarlimab, Sintilimab, Tislelizumab, JS-003, Toripalimab, AGEN-2034, APL-501, CS-1003, Nivolumab, AK 105, AK-112, Lipustobart, Camrelizumab, Zimberelimab, Sasanlimab, RO 7247669, QL 1706, HLX-10, Retifanlimab, QL1604, RK-001, GNUV-205, PBP-2102 and others.

Dive deep into rich insights for new Anti-CD279 (PD-1) antibody, visit @ Emerging Anti-CD279 (PD-1) Antibody 

Table of Contents

For further information on the Anti-CD279 (PD-1) antibody pipeline therapeutics, reach out @ Anti-CD279 (PD-1) Antibody Drugs

Related Reports

PD-1 Inhibitor Pipeline

PD-1 Inhibitor Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key PD-1 inhibitor companies, including Genmab, RemeGen, Alphamab, OxSonics therapeutics, Light Chain Bioscience, ImmuneOnco Biopharma, Alpine Immune Sciences, Shanghai Henlius Biotech, Inc., Ocean Biomedical, Akeso Biopharma, Lyvgen Biopharma, Prestige Biopharma, ONO PHARMACEUTICAL CO., LTD., among others.

PD-1 and PD-L1 Inhibitors Competitive Landscape

PD-1 and PD-L1 Inhibitors Competitive Landscape – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key PD-1 and PD-L1 inhibitors companies, including Merck, Laekna Therapeutics, Genentech, Tracon Pharmaceuticals Inc., Celgene, MedImmune, Hangzhou Sumgen Biotech, Lepu Biopharma, Harbour BioMed, Curis, BeiGene, Apollomics, Agenus, Boehringer Ingelheim, Jounce Therapeutics, Seagen Inc., Ascletis Pharma Inc., Secarna Pharmaceuticals GmbH & Co. KG, Arbutus Biopharma, among others.

CTLA-4 Inhibitors Competitive Landscape

CTLA-4 Inhibitors Competitive Landscape – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key CTLA-4 inhibitors companies, including Innovent Biologics, Alphamab Oncology, Agenus, Harbour BioMed, AstraZeneca, Alpine Immune Sciences, Henlix Biotech, DotBio, TrueBinding, Ocean Biomedical, Xencor, Molecular Templates, among others.

JAK Inhibitors Competitive Landscape

JAK Inhibitors Competitive Landscape – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key JAK inhibitors companies, including Pfizer, Sierra Oncology, Theravance Biopharma, Dizal Pharmaceutical, Aclaris Therapeutics, Celon Pharma, Incyte Corporation, AbbVie, Galapagos, among others.

TIGIT Inhibitors Competitive Landscape

TIGIT Inhibitors Competitive Landscape – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key TIGIT inhibitors companies, including Merck Sharp & Dohme, Bristol-Myers Squibb, BeiGene, Arcus Biosciences, iTeos Therapeutics, Mereo BioPharma, Phio Pharmaceuticals, Bio-Thera Solutions, Compugen, among others.

Other Trending Reports

T-Cell Prolymphocytic Leukemia Market | Acral Lentiginous Melanoma Market | Malt Lymphoma Market | Primary Progressive Multiple Sclerosis Ppms Market | 3d Cardiac Mapping System Market | Adult Growth Hormone Deficiency Market | Angioedema Market | Pain Management Devices Market | Allergic Rhinoconjunctivitis Market | Multiple Myeloma Market | Blood Gas And Electrolyte Analyzers Market | Helicobacter Pylori Infection Market | Helicobacter Pylori Infections Market | Cardiac Amyloidosis Market | Cardiac Resynchronization Therapy Device Market | Cerebral Aneurysm Market | Anemia In Ckd Market | Capnography Device Market | Cutaneous T-cell Lymphoma Market | Chronic Hepatitis B Virus Market | Ventricular Hypertrophy Market | Parkinson’s Disease Market |  Penicillinbinding Proteins Market | Critical Limb Ischemia Market | Hemophilia B Market | Cardiotoxicity Market | Xerostomia Market | Alopecia Market | Asmd Market | Hypothalamic Obesity Market | Chronic Cutaneous Ulcer Market | Chronic Insomnia Market | Adalimumab Biosimilar Market   | Arbovirus Infection Market | Artificial Pancreas Device System Market | Dental Equipment Market | Gluten Sensitivity Market | Hypothyroidism Market | Inflammatory Bowel Disease Market | Mayus Kinase Jak Inhibitors Market | Mild Dry Eye Market | Mucopolysaccharidosis Market | Oncolytic Virus Cancer Therapy Market | Pyoderma Gangrenosum Market | Transdermal Drug Delivery Devices Market | Intrathecal Pumps Market | Hedgehog Pathway Inhibitors Market | Yellow Fever Market | Laryngeal Cancer Market | Female Infertility Market | Gender Dysphoria Market | Chronic Brain Damage Market | Spain Healthcare Outlook Market | Malignant Fibrous Histiocytoma Market | Bowen’s Disease Market  |  Cartilage Diseases Market  |  Charcot-Marie-Tooth Disease Market  |  Cryptococcosis Market  |  Dental Lasers Market  |  Diabetes Market  |  Diverticulitis Market  |  Down Syndrome Market  |  Endocarditis Market  |  Extracorporeal Circulation System Market  |   Gastro Intestinal Bleeding Market  |  Gene Therapy for Ocular Rare Disease Market  |  Germ Cell Tumor Market  |  India Healthcare Outlook  |  Insulin Glargine Biosimilar Insight  |  Listeriosis Market  |  Liver Angiosarcoma Market | Lactose Intolerance Market | Meningococcal Meningitis Market | Radiodermatitis Market | Neuroendocrine Tumors Market | Intraocular Lymphoma Market | B-Cell Maturation Antigen Targeted Therapies Market | Atherosclerosis Market | Polycystic Ovarian Syndrome Market | Acute Myeloid Leukemia Market | Intraocular Lymphoma Market | Uveitis Market | Sepsis Market | Autoimmune Hepatitis | Primordial Dwarfism Market | Non-cystic Fibrosis Bronchiectasis Market | Microsatellite Stable Colorectal Cancer Market | Cystinuria Market | Deep Vein Thrombosis Market | Sialidosis Market | Blood Glucose Monitoring Systems Market | Chronic Rhinosinusitis Phenotype With Nasal | Polyps Market | Severe Hypoglycemia Market | Breast Pumps Market | Aids Dementia Market | Invasive Candidiasis Market | Severe Asthma | Fosmanogepix | Low Grade Glioma | Hand Eczema | Ulcerated Necrobiosis Lipoidica (uNL) | Molybdenum cofactor deficiency (MOCOD) – Type A | Sjogren’s Disease | Anorexia Nervosa (AN) | Generalized Myasthenia Gravis | Seasonal Influenza | Underactive Bladder | Gastrointestinal Stromal Tumor (GIST) Epidemiology | Adrenocortical Carcinoma | Monkeypox Market | Pars Planitis Market | Patient Monitoring Devices Market | Typhoid Market | Zika Virus Market | Opioid Use Disorder Market 

Related Healthcare Services

Healthcare Consulting

Healthcare Competitive Intelligence Services

Healthcare Asset Prioritization Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. 

Connect with us at LinkedIn